Impact of cumulative cisplatin dose in childhood nasopharyngeal carcinoma based on neoadjuvant chemotherapy response in the intensity-modulated radiotherapy era: a real-world study

Table 2 Multivariate analysis of prognostic factors for the entire group

Endpoint	Variable	HR	95% CI for HR	P value^a
DFS	CC-CCD (< 160 vs. ≥ 160 mg/m²)	0.26	0.10–0.65	0.004
	T stage (T1–3 vs. T4)	2.66	1.07–6.62	0.036
	EBV DNA (< 4000 vs. ≥ 4000 copy/mL)	3.35	1.11–10.16	0.032
	Smoking history (no vs. yes)	2.53	0.72–8.92	0.148
DMFS	CC-CCD (< 160 vs. ≥ 160 mg/m²)	0.28	0.10–0.81	0.018
	T stage (T1–3 vs. T4)	2.34	1.03–5.62	0.041
	EBV DNA (< 4000 vs. ≥ 4000 copy/mL)	3.27	1.02–9.60	0.046
	Smoking history (no vs. yes)	3.50	0.97–12.64	0.056
OS	T stage (T1–3 vs. T4)	2.94	1.01–4.27	0.046
OS	EBV DNA (< 4000 vs. ≥ 4000 copy/mL)	3.72	0.83–16.67	0.057

HR hazards ratio, 95% CI 95% confidence interval, CC-CCD cumulative cisplatin dose during concurrent chemoradiotherapy, EBV Epstein-Barr virus, DFS disease-free survival, DMFS distant metastasis-free survival, OS overall survival
^aP values were calculated using an adjusted Cox proportional hazards model

ISSN: 1475-2867